Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2012

CIN85 phosphorylation is essential for EGFR ubiquitination and
sorting into multivesicular bodies
Barbara Schroeder
Mayo Clinic

Subhashini Srivatsan
Washington University School of Medicine in St. Louis

Andrey Shaw
Washington University School of Medicine in St. Louis

Daniel Billadeau
Mayo Clinic

Mark A. McNiven
Mayo Clinic

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Schroeder, Barbara; Srivatsan, Subhashini; Shaw, Andrey; Billadeau, Daniel; and McNiven, Mark A., ,"CIN85
phosphorylation is essential for EGFR ubiquitination and sorting into multivesicular bodies." Molecular
Biology of the Cell. 23,18. 3602-3611. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1197

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

MBoC | ARTICLE

CIN85 phosphorylation is essential for EGFR
ubiquitination and sorting into multivesicular
bodies
Barbara Schroedera,b, Subhashini Srivatsanc, Andrey Shawc, Daniel Billadeaud,
and Mark A. McNivena,b
a

Department of Biochemistry and Molecular Biology, bCenter for Basic Research in Digestive Diseases, and
Department of Immunology, Mayo Clinic, Rochester, MN 55905; cDepartment of Pathology and Immunology,
Washington University School of Medicine, St. Louis, MO 63110

d

ABSTRACT Ubiquitination of the epidermal growth factor receptor (EGFR) by cbl and its
cognate adaptor cbl-interacting protein of 85 kDa (CIN85) is known to play an essential role
in directing this receptor to the lysosome for degradation. The mechanisms by which this
ubiquitin modiﬁcation is regulated are not fully deﬁned, nor is it clear where this process occurs. In this study we show that EGFR activation leads to a pronounced src-mediated tyrosine
phosphorylation of CIN85 that subsequently inﬂuences EGFR ubiquitination. Of importance,
phospho-CIN85 interacts with the Rab5-positive endosome, where it mediates the sequestration of the ubiquitinated receptor into multivesicular bodies (MVBs) for subsequent degradation. These ﬁndings provide novel insights into how src- kinase–based regulation of a cbl
adaptor regulates the fate of the EGFR.

Monitoring Editor
Jean E. Gruenberg
University of Geneva
Received: Aug 2, 2011
Revised: Jun 18, 2012
Accepted: Jul 16, 2012

INTRODUCTION
The epidermal growth factor (EGF) receptor (EGFR) controls important cellular processes such as cellular adhesion, migration, and proliferation. Accordingly, overexpression of this receptor tyrosine kinase (RTK) is associated with the development of a variety of human
cancers (Roskoski, 2004; Sebastian et al., 2006). Therefore tight
regulation of EGFR levels, activation, and downstream signaling
cascades is essential. A mechanism used by cells to maintain normal
receptor levels is deliberate control of endocytic internalization, recycling, and degradation of the receptor both spatially and temporally (Zwang and Yarden, 2009).
It has been demonstrated that the cbl-mediated ubiquitination
of the EGFR is essential and sufﬁcient for proper sorting and target-
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ing to the lysosome for degradation (Ettenberg et al., 2001; Huang
et al., 2006) but is dispensable for EGFR internalization (Huang
et al., 2006; Pennock and Wang, 2008). Although partial ubiquitination of the receptor is believed to occur at the plasma membrane
(Stang et al., 2000; de Melker et al., 2001), this posttranslational
modiﬁcation is not required for internalization (Huang et al., 2007)
nor does it appear to require internalization (de Melker et al., 2001).
Thus ubiquitination may actually perform its receptor-targeting
function downstream of the initial endocytic event during progression from early endosomes to late endosomes/multivesicular bodies (MVBs; Ravid et al., 2004). This cbl-dependent process is augmented by the action of a structural adaptor protein, cbl-interacting
protein of 85 kDa (CIN85), which tethers cbl to the endocytic machinery in an EGF-dependent manner (Dikic, 2002). A number of
studies have suggested that CIN85 participates in both the initial
steps of EGFR internalization (Soubeyran et al., 2002; Schmidt et al.,
2004) and also in receptor trafﬁcking and degradation (de Melker
et al., 2001; Kowanetz et al., 2004; Schroeder et al., 2010). Of interest, it has recently been shown that knockdown of CIN85 results in
a decrease in EGFR ubiquitination (Ronning et al., 2011), although
the underlying mechanism has not been investigated. Of greater
importance, it also remains unclear whether the CIN85–cbl interaction is essential for receptor ubiquitination and appropriate downstream trafﬁcking. Indeed, several key steps in this important
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FIGURE 1: CIN85 is phosphorylated upon EGF stimulation in a src-dependent manner. (A) Representative blot showing
EGF-induced CIN85 phosphorylation. CIN85 was immunoprecipitated from HuH7 cells stimulated with EGF for the
indicated time points before Western blot analysis with an anti-phosphotyrosine antibody. (B) A substantial increase in
tyrosine phosphorylation was observed by 30–60 min poststimulation and quantitated from three independent
experiments as described in A. The pTyr signal was normalized to the amount of total precipitated CIN85 in each lane,
and the data are represented as mean o SE. (C) Representative blot showing induction of CIN85 phosphorylation by
overexpression of active src (srcY530F) but not kinase-dead src (srcK297M) in HeLa and HuH7 cells under full serum
conditions. (D) Representative blot showing rescue of CIN85 phosphorylation in SYF cells by reexpression of active src
(srcY530F) but not kinase-dead src (srcK297M).

process remain nebulous and need to be deﬁned further. For example, how does activation of the EGFR induce formation of the
CIN85–cbl complex, what downstream signaling events stimulate
this interaction, and where in the endocytic pathway does this occur? Finally, what are the consequences of preventing this stimulated interaction on EGFR trafﬁc to the lysosome?
In this study, we report a novel EGF-induced, Tyr-based phosphorylation of CIN85 that is mediated by src kinase 30 min poststimulation, suggesting that this event occurs at a later endocytic
compartment. Interference with the src-regulated phosphorylation
of CIN85 results in decreased association of this adaptor with both
Rab5 at the early endosomes and the cbl ligase. Most important,
preventing CIN85 phosphorylation signiﬁcantly reduces ubiquitination of the EGFR and leads to its accumulation in early endosomes.
These ﬁndings reveal a novel src–CIN85-centric signaling pathway
that regulates EGFR trafﬁcking and subsequently its degradation.

RESULTS
CIN85 is a src substrate that is phosphorylated upon EGF
stimulation
CIN85 plays an important role in EGFR down-regulation (Haglund
et al., 2002; Soubeyran et al., 2002; Kowanetz et al., 2003, 2004),
Volume 23 September 15, 2012

although it is unclear whether this is a regulated process. Given that
CIN85 contains four potential Tyr phosphorylation sites, we tested
whether CIN85 might be Tyr phosphorylated upon EGF stimulation.
To this end, we stimulated HuH7 cells with 50 ng/ml EGF, and we
immunoprecipitated endogenous CIN85 at different time points
and immunoblotted for phospho-Tyr. As shown in Figure 1A, CIN85
is indeed Tyr phosphorylated in a stepwise manner after EGF stimulation, not immediately, but at later time points (peak around 30–
60 min post EGF; Figure 1, A and B; **p < 0.05).
Because src is activated upon EGF stimulation (Oude Weernink
et al., 1994) and is a known binding partner of the CIN85 homologue CD2AP (Kirsch et al., 1999), we tested whether this kinase
could mediate CIN85 phosphorylation. We pursued this by expressing either constitutively active src (srcY530F) or kinase-dead src (src
K297M) in HeLa and HuH7 cells and then monitoring CIN85 phosphorylation independent of EGF stimulation. Although wt src did
not result in detectable CIN85 phosphorylation, overexpression of
constitutively active src induced strong CIN85 phosphorylation,
whereas the kinase-dead form was unable to do so (Figure 1C). This
suggests that active src alone is sufﬁcient to promote CIN85 phosphorylation and can mimic EGF-induced CIN85 phosphorylation. To
conﬁrm these results, we used SYF cells (src/yes/fyn triple-knockout
phospho-CIN85 regulates EGFR sorting
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FIGURE 2: A phospho-defective CIN85 mutant, CIN85-4F, does not interfere with EGFR endocytosis. (A) Mutation of
four key tyrosines in CIN85 (CIN85-4F) prevents phosphorylation of CIN85. FLAG-tagged CIN85wt or CIN85-4F was
precipitated from HeLa cells coexpressing active src (srcY530F), and the CIN85 phosphorylation status was assessed by
Western blot analysis. (B) Overexpression of CIN85-4F does not affect EGFR endocytosis. Representative images of
RhEGF internalization in HuH7 cells expressing either CIN85wt (asterisk, top) or -4F (asterisk, bottom). Internalization
was allowed for 15 min, and cells were acid stripped to visualize only internalized ligand. (C) Quantitation of three
independent experiments as described in B. The data are represented as mean o SE. (D) Representative blot of a
surface biotinylation assay used to examine the effects of CIN85wt and -4F on EGFR endocytosis. HuH7 cells expressing
FLAG-CIN85wt or -4F were stimulated for the indicated time points; surface proteins were biotinylated and precipitated
using streptavidin (SA)-coated beads. The amount of total and surface EGFR was assessed by Western blot analysis.
(E) Quantitation of four independent experiments as described in D. The data are represented as mean o SE.

mouse embryonic ﬁbroblasts) for rescue experiments, predicting
that without src there would be no CIN85 phosphorylation and that
with reexpression of active src CIN85 phosphorylation should be
rescued. Indeed, CIN85 was not phosphorylated in control SYF
cells, whereas its phosphorylation was restored by reexpressing active src but not kinase-dead src (Figure 1D). Of interest, reexpression
of wt src alone in these cells did not result in detectable CIN85
phosphorylation, suggesting that activation of this kinase is needed.
To test whether EGF-induced src activation might induce CIN85
phosphorylation in SYF cells, we expressed wt src kinase in these
cells and assessed CIN85 phosphorylation with or without EGF
addition. As shown in Supplemental Figure S1A, CIN85 was phosphorylated in a src- and EGF-dependent manner, revealing an
EGFR–src cascade that leads to CIN85 phosphorylation. We further
conﬁrmed the src dependence of CIN85 phosphorylation by a pharmacological approach using the src inhibitor SU6656. Compared to
control cells treated with dimethyl sulfoxide (DMSO), the SU6656
cells exhibited signiﬁcantly reduced CIN85 phosphorylation (Supplemental Figure S1B).
Taken together, those data suggest that CIN85 is Tyr phosphorylated upon EGF stimulation in a src-dependent manner.
3604 | B. Schroeder et al.

Inhibition of CIN85 phosphorylation does not affect EGFR
endocytosis
To determine the functional relevance of CIN85 phosphorylation,
we generated a phospho-defective CIN85 mutant and then examined its effects on EGFR endocytosis and trafﬁcking. CIN85 has
four potential Tyr phosphorylation sites—Y10, Y109, Y271, and
Y278—all of which were converted to phenylalanine by site-directed
mutagenesis to produce a mutant we termed CIN85-4F (CIN85Y10/109/271/278F). To ensure that this CIN85 mutant is not Tyr
phosphorylated, we coexpressed active src with either FLAGCIN85wt or -4F and assessed the Tyr-phosphorylation status of the
CIN85wt and mutant. As shown in Figure 2A, CIN85wt is Tyr phosphorylated in the presence of active src, whereas the CIN85-4F mutant is not. It is important to note that the defective phosphorylation
of the CIN85-4F mutant is not due to impaired src binding, since the
mutant bound equally as well to src as the wt protein (Supplemental
Figure S1C).
To determine the functional consequences of the CIN85-4F
phospho-mutant, we ﬁrst examined the effects of CIN85wt and -4F
on EGFR endocytosis both by immunoﬂuorescence staining (IF)
and biochemically. For the IF analysis, HuH7 cells expressing either
Molecular Biology of the Cell

FIGURE 3: Inhibition of CIN85 phosphorylation causes a marked retention of EGFR at the early endosome. (A) RhEGF
trafﬁcking assay in HuH7 expressing GFP-Rab5 (green) together with either FLAG-CIN8wt or FLAG-CIN85-4F. CIN85wt
and mutant proteins were expressed at comparable levels. Arrowheads point to the Rab5 endosomes positive for
RhEGF, which are decreased substantially in wt-expressing cells as the ligand trafﬁcs through the endocytic pathway. In
contrast, cells expressing the CIN85-4F mutant exhibit a marked retention of RhEGF in the Rab5 endosome. Insets 1–6
show magniﬁcations of the boxed areas in the overview images. Bars, 10 μm. (B) Quantitation of the amount of RhEGF
colocalizing with GFP-Rab5–positive endosomes at various time points in HuH7 cells expressing GFP-Rab5 together
with either CIN85wt (blue line) or CIN85-4F (red line). Almost no transport of ligand from the Rab5 endosome is
observed even after a 2-h chase. For each condition q30 cells were counted, and the data are represented as mean o SE.

FLAG-CIN85wt or the -4F mutant were incubated with rhodamine–
EGF (RhEGF) for 20 min at 37°C, and the amount of internalized
RhEGF was quantitated. As shown in Figure 2, B and C, expression
of either CIN85wt or CIN85-4F did not result in any signiﬁcant inhibition of EGFR endocytosis. These data were conﬁrmed by surface biotinylation assays showing that EGFR was internalized at
similar levels in both CIN85wt- and mutant-expressing cells after
short pulses of EGF (Figure 2, D and E). Taken together, these data
show that preventing CIN85 phosphorylation does not affect EGFR
endocytosis, and they are consistent with our previous observations that this adaptor participates in the later steps of endocytic
trafﬁcking.

Inhibition of CIN85 phosphorylation impairs EGFR exit
from the early endosome and delays EGFR degradation
Given that EGFR internalization is not inﬂuenced by overexpression
of the phospho-defective CIN85-4F mutant, we examined whether
CIN85 phosphorylation might regulate EGFR endocytic trafﬁcking.
To this end, we monitored EGFR transport by assessing the colocalization of RhEGF with early and late endosomal markers in CIN85wtand mutant-expressing HuH7 cells. Early versus late endosomes
were visualized using green ﬂuorescent protein (GFP)–Rab5 or GFPRab7, respectively. As shown in Figure 3, A and B, in cells expressing
CIN85wt, RhEGF accumulates in early endosomes within 15 min
(Figure 3A, inset 1), exits after 45–60 min (Figure 3A, insets 2 and 3),
and is degraded by 2 h. In contrast, CIN85-4F–expressing cells do
not exhibit alterations in the transit of the EGFR to the early endosome (Figure 3A, inset 4), but instead show a signiﬁcant delay in
EGFR trafﬁcking out of the early endosome. This leads to retention
of RhEGF in the early endosomal compartment even after the 2-h
chase period (Figure 3A, insets 5 and 6, B; **p < 0.0005). Consistent
with these data, we observed a signiﬁcant delay in EGFR transit to
late endosomes when CIN85 Tyr phosphorylation was disrupted. In
Volume 23 September 15, 2012

CIN85wt-expressing cells, RhEGF localizes to late endosomes after
a 1-h chase (Figure 4A, inset 2) and has trafﬁcked through this endocytic step to a degradative compartment by 2 h (Figure 4A, inset 3).
As CIN85-4F–expressing cells accumulate RhEGF in the early endosomes, this leads to a signiﬁcant reduction in the transport of the
labeled ligand to the Rab7-positive late endosomal compartment
(Figure 4, A, insets 5 and 6, and B; **p < 0.0005). In addition, accumulation causes a delay in RhEGF degradation visualized by retention of the RhEGF signal even after a 2-h chase (Figure 4A, compare
insets 3 and 6).
Because our data suggest that the CIN85–cbl complex mainly
acts at the early endosomes and not necessarily at the initial endocytic pit, we visualized the components of this complex at the place
of action. It was previously shown that cbl indeed localizes to early
endocytic, EGFR-positive structures and remains associated with
the receptor throughout the endocytic route (Levkowitz et al., 1998;
de Melker et al., 2001; Visser Smit et al., 2009). It was also reported
that cbl preferentially localizes to the Hrs-positive subdomains of
early endosomes (Umebayashi et al., 2008). Therefore we chose Hrs
as an early endosomal marker for our cbl colocalization studies. As
shown in Supplemental Figure S2a, cbl localized to Hrs-positive endosomes 15–30 min after EGF.
Because it is difﬁcult to localize CIN85 to endosomal structures in
ﬁxed cells, most likely due to the transient nature of this association,
live-cell imaging was used to assess the localization of CIN85 on
early endosomes. Subsequently, HeLa cells were cotransfected with
mCherry-CIN85 and active, GFP-tagged Rab5 (GFP-Rab5Q79L) as
performed previously (Schroeder et al., 2010). Before imaging, cells
were stimulated with 50 ng/ml EGF for 20 min, and the images were
acquired 25–30 min after EGF addition. As shown in Supplemental
Figure S2B, CIN85 localized to Rab5-positive early endosomes
under these experimental conditions. To support these morphological studies, we performed coimmunoprecipitation assays. To
phospho-CIN85 regulates EGFR sorting
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FIGURE 4: Inhibition of CIN85 phosphorylation delays delivery of EGFR to late endosomes. (A) RhEGF trafﬁcking assay
in HuH7 expressing GFP-Rab7 (green) as a marker for the late endosome together with either FLAG-CIN85wt or
FLAG-CIN85-4F. CIN85wt and mutant proteins were expressed at comparable levels. Arrowheads point to the Rab7
endosomes positive for RhEGF, which are markedly increased by 60 min after chase in wt-expressing cells but minimized
in the CIN85 mutant–expressing cells. Insets 1–6 show magniﬁcations of the boxed areas in the overview images. Bars,
10 μm. (B) Quantitation of the amount of RhEGF colocalizing with GFP-Rab7–positive endosomes at various time points
in HuH7 cells expressing GFP-Rab7 together with either CIN85wt (blue line) or CIN85-4F (red line). Disruption of the
CIN85–cbl complex caused a signiﬁcant delay in EGFR trafﬁcking to the late endosomes. For each condition q30 cells
were counted, and the data are represented as mean o SE.

this end, we transfected HeLa cells with GFP-Rab5 and examined
the interaction with endogenous CIN85 after EGF stimulation. Of
interest, CIN85 interacts with Rab5 in an EGF-dependent manner
(Supplemental Figure S2C; p < 0.05). Furthermore, we ﬁnd that
this interaction is dependent on the phosphorylation status of
CIN85, as GFP-Rab5 and FLAG-CIN85wt, but not the CIN85-4F
mutant protein, are seen to associate in response to EGF stimulation (Supplemental Figure S2D; p < 0.0005). All of these ﬁndings
are consistent with the concept of a functional src-activated
CIN85–cbl complex that regulates the trafﬁc of EGFR at the Rab5
endosome.
To conﬁrm the IF-based results, we performed EGFR degradation assays in HuH7 cells expressing either CIN85wt or the phospho-defective CIN85-4F mutant. Again, we observed a clear delay of EGFR degradation in the mutant compared with the
wt-expressing cells (Figure 5, A and B; p < 0.05). EGFR protein
levels were decreased by ^90% within 90 min in CIN85wtexpressing cells, whereas cells expressing the CIN85-4F mutant
retained nearly 50% of their EGFR at the same time point. Because inhibition of the src-dependent phosphorylation of CIN85
delayed EGFR degradation, we also determined the involvement
of src in that process. To this end, we performed biochemical
EGFR degradation assays in SYF cells with or without reexpression of wt src, expecting that reintroducing src would somehow
restore normal rates of receptor degradation in these cells. Indeed, reexpression of src wt into SYF cells accelerated EGFR
degradation threefold to fourfold compared with control cells
(Figure 5, C and D; p < 0.05). Taken together, these ﬁndings suggest that the phosphorylation of CIN85 is necessary for proper
postendocytic EGFR trafﬁcking, and impairment of CIN85 Tyr
phosphorylation causes a delay in EGFR degradation due to retention of the receptor in early endosomes.
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CIN85 phosphorylation is essential for EGFR ubiquitination
and appropriate receptor sorting into MVBs
CIN85 was originally identiﬁed as a cbl-binding protein by Take
et al. (2000), and a recent study demonstrated that a disruption of
this interaction results in an impairment of EGFR trafﬁcking from the
early endosome (Schroeder et al., 2010). Because expression of the
phospho-defective CIN85-4F used in this study induces the same
block in EGFR trafﬁc (Figure 3), we postulated that src-dependent
phosphorylation of CIN85 might regulate the cbl interaction. To this
end, we coexpressed hemagglutinin (HA)-cbl with either FLAGCIN85wt or -4F and stimulated it with 50 ng/ml EGF for 30 min,
followed by a cbl immunoprecipitation and quantitation of associated CIN85 by Western blot. Of importance, the CIN85-4F mutant
showed substantially less binding (^80% reduction; p < 0.0005) to
cbl than did the wt protein (Figure 6A). We observed a similar reduction in binding by assessing the interaction of endogenous cbl with
CIN85wt or -4F (Supplemental Figure S1D; p < 0.0005). Given that
cbl is the major E3 ligase responsible for ubiquitination of the EGFR,
we next tested whether impairment of CIN85 phosphorylation
might affect EGFR ubiquitination. Subsequently, HA-ubiquitin
(HA-Ub) was coexpressed with either CIN85wt or the -4F mutant,
and the ubiquitination status of EGFR was assessed after stimulation
with 50 ng/ml EGF for 30 min. Of interest, expression of the
CIN85-4F mutant caused a signiﬁcant (^70%; p < 0.05) reduction in
EGFR ubiquitination compared with wt-expressing cells (Figure 6B),
suggesting that a phospho-dependent interaction between CIN85
and cbl is essential for appropriate ubiquitination of the receptor.
Appropriate ubiquitination and trafﬁcking of the EGFR regulate
sorting of the receptor into intraluminal vesicles (ILVs) of MVBs, an
important step in EGFR degradation and down-regulation. Because
both of these processes are signiﬁcantly impaired in cells expressing
the CIN85-4F phosphorylation-defective mutant, it seemed likely that
Molecular Biology of the Cell

a CIN85-short hairpin RNA (shRNA)–encoding lentivirus to ensure a stable and nearly
complete knockdown of CIN85 (Supplemental Figure S3A), allowing us to test
EGFR endocytosis and trafﬁcking in the
context of CIN85 deﬁciency. As reported
previously (Schroeder et al., 2010), EGFR
endocytosis was only mildly affected in
these cells compared with cells transfected
with a nontargeting control shRNA (Supplemental Figure S3, B and C). Furthermore,
we observed a missorting of the receptor to
the limiting membrane of enlarged endosomes (Supplemental Figure S3, D and E),
as well as a delay in transport of the receptor to late endosomes (Supplemental Figure S3, F and G) and a concomitant reduction in EGFR degradation (Supplemental
Figure S3, H and I). Taken together, the
knockdown data conﬁrm that CIN85 is important in conducting early to late endosomal EGFR trafﬁcking.

DISCUSSION

FIGURE 5: Phosphorylation of CIN85 is required for efﬁcient degradation of EGFR. HuH7 cells
expressing FLAG-CIN85wt or FLAG-CIN85-4F (A, B) or SYF cells with or without reexpression of
src wt (C, D) were serum starved for 4 h in the presence of 50 μg/ml CHX and treated with
50 ng/ml EGF plus CHX for the indicated time points. Equal amounts of each sample were
analyzed by Western blot (A and C) and show a strong persistence of EGFR levels in cells
expressing the mutant CIN85 (A) and an acceleration of EGFR degradation in SYF cells
reexpressing src wt (C). (B, D) Quantitation of q4 independent EGFR degradation assays
comparing CIN85wt- and CIN85-4F–expressing cells demonstrating an 8- to 10-fold increase in
the retention of intact EGFR in the mutant-expressing cells. SYF cells with src wt show three- to
fourfold faster receptor degradation compared with control cells as assessed by quantitation of
three independent experiments. The amount of EGFR in each sample was normalized to actin,
and the data are represented as mean o SE.

CIN85 phosphorylation could play a role in sorting of the receptor
into ILVs of MVBs. To test the efﬁcacy of MVB sorting in the CIN85
mutant–expressing cells, we used an approach described by Lobert
et al. (2010) and compared EGFR sorting into MVBs in cells coexpressing GFP-tagged Rab5-Q79L with either CIN85wt or -4F mutant
or control cells expressing GFP-Rab5-Q79L alone. Overexpression of
active Rab5 is well known to induce enlargement of early endosomes
(Stenmark et al., 1994), which facilitates resolution of the MVB lumen
from the vesicle limiting membrane. Graphically, inhibition of CIN85
phosphorylation greatly affected MVB sorting of the EGFR (Figure 6,
C and D). In control (Figure 6C, inset 1) and CIN85wt-expressing cells
(Figure 6C, inset 2), the majority of EGFR was sorted into the lumen
of the early endosomes, whereas in CIN85-4F–expressing cells EGFR
was missorted to the limiting membrane (Figure 6C, inset 3). Quantiﬁcation revealed that MVB sorting of EGFR in cells expressing the
phospho-defective CIN85 mutant was reduced by >50% compared
with control cells (Figure 6D; **p < 0.0001). These data indicate that
CIN85 phosphorylation is necessary for proper sorting of EGFR into
MVBs for subsequent trafﬁcking to late endosomes and lysosomes
for degradation.
The role of CIN85 in early endosomal sorting and trafﬁcking of
the EGFR was further supported by experiments using 3T9 cells
depleted of endogenous CIN85. These cells were transfected with
Volume 23 September 15, 2012

In this study, we provide novel insights into
the molecular mechanisms by which the endocytosed EGF receptor is directed toward
the degradative pathway upon ligand stimulation. Speciﬁcally, we identify a novel
EGF-induced, src-mediated tyrosine phosphorylation of the endocytic adaptor protein CIN85 (Figures 1 and 2 and Supplemental Figure S1, A–C). This phosphorylation
event mediates the interaction of CIN85
with the E3 ubiquitin ligase, cbl, and is required for appropriate EGFR ubiquitination,
sorting, and degradation (Figures 3–6 and
Supplemental Figure S1D).

CIN85 function: from receptor internalization
to degradation
Previously it was shown that the activated EGFR binds to cbl, which,
in turn, recruits CIN85 to the endocytic pit. This trimeric EGFR–cbl–
CIN85 complex was assumed to trafﬁc through the endocytic pathway for subsequent degradation. Thus CIN85 action has been implicated mainly in early stages of endocytic internalization (Haglund
et al., 2002; Soubeyran et al., 2002).
In contrast, we observed that CIN85 appears to act largely in
postendocytic sorting and that the src-mediated phosphorylation
of this adaptor, which peaks at ^30–60 min after EGF stimulation,
is particularly important for later steps of endocytic receptor trafﬁc.
Indeed, blocking CIN85 Tyr phosphorylation has no obvious effect
on EGFR endocytosis but instead affects the efﬁcient sorting and
degradation of the EGFR (Figures 2–6). These observations are in
agreement with a previous study reporting the participation of
CIN85 in late endosomal trafﬁcking via an interaction with dynamin
2 and Rab7 (Schroeder et al., 2010). It also conﬁrms recent observations from our lab and by others showing that RNA interference–
mediated knockdown of CIN85 does not affect EGFR endocytosis
(Supplemental Figure S3A; Schroeder et al., 2010; Ronning et al.,
2011). Consistent with this premise, expression of a phosphorylation-deﬁcient mutant of CIN85 (CIN85-4F) resulted in retention of
phospho-CIN85 regulates EGFR sorting
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FIGURE 6: Inhibition of CIN85 phosphorylation results in reduced EGFR ubiquitination and missorting of the receptor
to the limiting endosomal membrane. (A) Representative blot of a coimmunoprecipitation assay from HeLa cells
coexpressing HA-cbl and either FLAG-CIN85wt or FLAG-CIN85-4F that were treated with 50 ng/ml EGF for 30 min. The
levels of coprecipitated CIN85 were normalized to that of precipitated cbl, and the average amount of cbl-bound
CIN85-4F relative to the wt from three independent experiments is shown. (B) Representative blot of an EGFR
ubiquitination assay in HeLa coexpressing HA-Ub and either FLAG-CIN85wt or FLAG-CIN85-4F. Cells were treated with
50 ng/ml EGF for 30 min. The amount of HA-Ub was normalized to the amount of precipitated EGFR, and the average
amount of ubiquitinated EGFR in CIN85-4F–expressing cells relative to wt-expressing cells from three independent
experiments is shown. (C) IF images of EGFR sorting into MVBs in HeLa cells expressing either GFP-Rab5Q79L alone
(control) or together with FLAG-CIN85wt or FLAG-CIN85-4F. Cells were treated with 50 ng/ml EGF for 30 min. Insets
1–3 show higher-magniﬁcation images of the boxed areas in the overview pictures. Bars, 5 μm. (D) Quantitation of three
independent ILV sorting assays as described in C. Localization of EGFR was assessed in >30 cells, and the data are
represented as mean o SE.

EGFR in early endosomes due to the missorting of the receptor to
the endosomal limiting membrane (Figures 3 and 6). Of importance, depletion of CIN85 induced the same EGFR trafﬁcking defects as did inhibition of CIN85 phosphorylation, supporting an
important role of CIN85 in EGFR sorting as well as degradation
(Supplemental Figure S3, B–I). Taken together, these data provide
novel insights into the regulation of CIN85 action and indicate that
this adaptor protein plays an active role in EGFR sorting, most
3608 | B. Schroeder et al.

likely in concert with Rab5 and cbl at the early endosome (Figures
6 and Supplemental Figure S2). Identifying Rab5 as an interaction
partner of CIN85 also underlines the importance of CIN85 at the
early endosome. Thus this interaction could ensure that the endocytosed EGFR, likely in complex with cbl and CIN85 as reported
previously (Dikic, 2002), is recruited to the early endosome while
being retained to maximize the ubiquitination process for subsequent lysosomal sorting (Supplemental Figure S4, A and B). This
Molecular Biology of the Cell

idea is also strongly supported by a recent report by Ronning et al.
(2011) in which they demonstrated that CIN85 constitutively interacts with Hrs, which led them to speculate that in this context,
CIN85 might help in promoting assembly of ESCRT complexes to
facilitate EGFR sorting and degradation—a concept also proposed
by Zhang et al. (2009). Further studies will be needed to determine
the exact mechanism by which CIN85 regulates EGFR sorting at
early endosomes.
Because the CIN85 phosphorylation, and potentially its interaction with cbl, occurs 30 min after EGF, it is possible that a participation in the initial receptor ubiquitination step is minimal. It
does remain unclear, however, why these processes/modiﬁcations
would even be partially initiated at the plasma membrane since
they are not essential for EGFR internalization. From the ﬁndings
in this study and others, we view CIN85 as a critical component of
a positive feedback loop at the early endosome that participates
in the activation of a cbl/EGFR ubiquitination complex (Supplemental Figure S4B). In this model, src-phosphorylated CIN85
increases the Ub-ligase activity of cbl at the early endosome, potentially by regulating src-mediated cbl phosphorylation as already
shown for cbl-c (Ryan et al., 2010). This increased cbl activation
would then promote a more complete EGFR ubiquitination that
promotes EGFR sorting into MVBs and targeting to the lysosome for
degradation. Loss of CIN85 phosphorylation, for example, by overexpressing the phospho-defective CIN85-4F mutant, would cause a
reduction in src-mediated cbl phosphorylation/activation and subsequent EGFR ubiquitination, leading to receptor missorting.

The CIN85–cbl interaction regulates EGFR ubiquitination
and sorting
As previously mentioned, several reports have implicated the
CIN895-cbl complex in EGFR endocytosis and down-regulation,
although it is unclear whether the CIN85–cbl interaction per se is
essential for proper receptor ubiquitination and sorting. A previous report showed that the CIN85–cbl interaction is dispensable
for EGFR ubiquitination (Soubeyran et al., 2002), whereas others
reported that depletion of CIN85 results in a decrease in EGFR
ubiquitination (Ronning et al., 2011) without providing mechanistic
insights into how and where this effect occurs. In contrast, we observed a substantial decrease in EGFR ubiquitination when the
CIN85–cbl complex was disrupted (Figure 6). We emphasize that
our data do not exclude the possibility that EGFR ubiquitination
could be initiated at the plasma membrane, as there is not a complete loss of this modiﬁcation upon disruption of the CIN85–cbl
complex. However, these ﬁndings agree with other studies showing that EGFR ubiquitination is not important for its internalization
(Huang et al., 2007). In general, the timing of EGFR ubiquitination
is still not completely deﬁned and might depend on the cell type
and experimental conditions. For example, the discrepancy between the mentioned studies and the data presented here could
be explained by the different time courses of the observed ubiquitination, as others measured the EGFR ubiquitination proﬁle in
HEK293T and CHO cells just 10 min after EGF stimulation compared with 30 min after EGF in HeLa cells in the present study. It is
likely, then, that the different studies observed distinct phases/
peaks of EGFR ubiquitination, as described by Pennock and Wang
(2008). Most important, we present a mechanistic insight into how
CIN85 could regulate EGFR ubiquitination, namely by regulating
the EGFR–cbl interaction. Taken together, our ﬁndings suggest
that the CIN85–cbl complex contributes signiﬁcantly toward the
second wave of EGFR ubiquitination that occurs downstream of
the initial ubiquitination in the endocytic event.
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In addition, the data in the present study strongly support the
concept that the CIN85–cbl interaction is required for proper EGFR
trafﬁcking and degradation, as prevention of CIN85 phosphorylation and thus CIN85–cbl complex formation greatly affects both
processes. This is consistent with our previous ﬁndings that disruption of the CIN85–cbl complex by overexpression of another
CIN85 mutant defective in cbl binding (CIN85B W l Y) also causes
retention of EGFR in early endosomes (Schroeder et al., 2010).
Thus, interfering with the CIN85–cbl complex either by mutating
the SH3-binding site (CIN85B W l Y) or preventing phosphorylation (CIN85-4F; Figure 2) results in the same physiological outcome. Our ﬁndings also agree with the published role for cbl on
the early endosome, where it controls early endosome fusion and
exit of the EGFR from the early endosome (Ravid et al., 2004;
Visser Smit et al., 2009). Several unanswered questions need to be
addressed in the future, however. For example, how is the CIN85–
cbl complex targeted to the early endosome? What are the implications of CIN85 phosphorylation for EGFR-dependent signaling?
In particular, how does phospho-CIN85 activate cbl? Does phospho-CIN85 also affect cbl–EGFR binding? Answering these questions will lead to better understanding EGFR trafﬁcking and might
help to develop new tools to speciﬁcally block distinct steps in
EGFR trafﬁcking.

MATERIALS AND METHODS
Cell culture and transfection
HeLa and HuH7 (human hepatocellular carcinoma) cells were incubated in MEM, supplemented with 10% fetal bovine serum (FBS),
1.5 g/l sodium bicarbonate, 50 U/mg penicillin plus 50 μg/ml streptomycin, 1r nonessential amino acids, and 1 mM sodium pyrophosphate. SYF cells were cultured in DMEM supplemented with 10%
FBS and 50 U/mg penicillin plus 50 μg/ml streptomycin. Cells were
transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions.

Generation of the knockdown 3T9 ﬁbroblasts
Control (ﬁreﬂy luciferase) and CIN85-speciﬁc shRNA duplexes
(Srivatsan and Shaw, unpublished data) were cloned into the pFLRu
lentivirus as previously described (Feng et al., 2010). Viral supernatants were generated in 293T cells by transfection of the lentiviral
plasmids with Lipofectamine 2000 (Invitrogen) and the packaging
plasmids as described (Feng et al., 2010). Pooled supernatants, harvested at 24 and 48 h posttransfection, were applied to 3T9 ﬁbroblasts with 8 μg/ml polybrene and spun at room temperature for 2 h
at 2000 rpm. Supernatants were replaced with fresh medium immediately after centrifugation. Transduction efﬁciency was assessed
48 h later by ﬂow cytometry, and yellow ﬂuorescent protein–positive
cells were sorted using a FACSAria II high-speed cell sorter (BD,
Franklin Lakes, NJ).
Cells were cultured in DMEM, supplemented with 10% FBS,
2 mM L-glutamine, 1r nonessential amino acids, and 50 U/mg penicillin plus 50 μg/ml streptomycin. Cells were transfected for immunoﬂuorescence analysis using Lipofectamine 2000 according to the
manufacturer’s instructions.

Protein puriﬁcation and glutathione S-transferase pull down
Glutathione S-transferase (GST) fusion proteins were expressed in
Escherichia coli BL21 cells and puriﬁed using glutathione-coated
beads (Amersham-Pharmacia Biotech, GE Healthcare Bio-Sciences,
Piscataway, NJ) according to the manufacturer’s instructions. Puriﬁed GST-src kinase was purchased from Cell Signaling Technology
(Beverly, MA).
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Pharmacological inhibition of src
Cells were pretreated with 5–10 μM SU6656 or DMSO as control for
2 h before immunoprecipitation of CIN85 for further analysis.

q30 cells were counted, and the statistical analysis was performed
as described before (Schroeder et al., 2010).

Antibodies and reagents
Immunoprecipitation
HeLa cells were plated in 100-mm Petri dishes and grown to 70–90%
conﬂuence. The cells were serum starved for 16 h before adding
EGF (50 ng/ml) for the indicated time points. Cell lysates were collected either in hypotonic lysis buffer (10 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid, pH 7.5, 10 mM NaCl, 1 mM KH2PO4,
5 mM NaHCO3, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM EDTA, 10 mM
sodium pyrophosphate, 1 mM Na3VO4, protease inhibitors) or RIPA
buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, protease inhibitors), sonicated, and centrifuged for 10 min at 14,000 rpm at 4°C. Between 500 and 800 μg of
lysate was added to 5 μg of antibody and incubated for 2 h at 4°C.
Antibody-bound complexes were precipitated by adding protein
A– or G–coated beads (Sigma-Aldrich [St. Louis, MO] and Santa
Cruz Biotechnology [Santa Cruz, CA], respectively) for 1 h at 4°C,
washed ﬁve times, and subjected to Western blot analysis.

The CIN85 antibody used for immunoprecipitation was generated
against amino acids 291–400 of CIN85 and kindly provided by
Daniel Billadeau (Mayo Clinic, Rochester, MN). All other antibodies were purchased from the following companies: anti-CIN85
from Upstate (Millipore, Billerica, MA), anti-GFP from Roche
(Indianapolis, IN), anti-actin and anti-GST from Sigma-Aldrich,
anti-EGFR (polyclonal), anti-FLAG, and anti-HA from Cell Signaling
Technology, anti-cbl (monoclonal) from BD Transduction Laboratories (Lexington, KY), anti-lamp1 (rat) and anti-EGFR (monoclonal) from Santa Cruz Biotechnology, anti-pTyr, clone 4G10, from
Millipore, and anti-Hrs from Bethyl Laboratories (Montgomery,
TX). GFP-Rab7 was kindly provided by Richard Pagano (Mayo
Clinic); GFP-Rab5wt and GFP-Rab5Q79L were provided by Bruce
Horazdovsky (Mayo Clinic). Rhodamine-EGF was purchased from
Invitrogen, and human EGF and cycloheximide were purchased
from Sigma-Aldrich.

EGFR ubiquitination

Plasmids

HeLa cells were cotransfected with HA-ubiquitin (HA-Ub) and
CIN85wt or mutants as indicated, serum starved overnight, and
then stimulated with 50 ng/ml EGF for the indicated time points.
Cells were lysed in a NP-40/N-ethylmaleimide (NEM) buffer (30 mM
Tris pH 7.4, 150 mM NaCl, 1% NP-40, 4 mM EDTA, pH 8, 10 mM
NaF, 1 mM Na3VO4, 1 mM NEM, protease inhibitors), sonicated,
and centrifuged for 10 min at 14,000 rpm at 4°C. From 0.5 to 1 mg
of lysate was added to 5 μg of EGFR antibody and immune precipitated as described earlier.

GST-CIN85ABC and FLAG-CIN85wt were described previously
(Schroeder et al., 2010). The CIN85-4F mutant (CIN85
Y10/109/271/278F) and GFP-tagged active Rab5 (GFP-Rab5Q79L)
were generated by site-directed mutagenesis using Pfu turbo
(Calbiochem, La Jolla, CA) according to the manufacturer’s instructions. mCherry-CIN85 was cloned into the HindIII/XhoI sites of
mCherry-C3 and veriﬁed by PCR and sequence analysis.

Surface biotinylation after EGF stimulation
EGFR surface biotinylation assays were performed as described previously (Schroeder et al., 2010).

Immunoﬂuorescence, image acquisition, and manipulation
Indirect immunoﬂuorescence, image acquisition, and manipulations
were performed as described previously (Schroeder et al., 2010).

RhEGF uptake, quantiﬁcation, and statistical analysis
RhEGF trafﬁcking assays and their quantitation were performed
as described in Schroeder et al. (2010). Brieﬂy, cells were serum
starved overnight in low serum medium (0.2% FBS), pretreated
with 50 μg/ml cycloheximide (CHX) for 1 h at 37°C, and then incubated with 100 ng/ml RhEGF plus CHX at 4°C for 45 min,
pulsed for 15 min at 37°C to allow endocytosis, and then washed
and chased for the indicated time points with low serum medium
plus CHX. Cells were ﬁxed and subjected to immunoﬂuorescence
analysis.

MVB sorting and quantitation
HeLa cells were cotransfected with GFP-tagged, constitutively active Rab5 (GFP-Rab5Q79L) and either FLAG-CIN85wt or FLAGCIN85-4F, serum starved overnight, and then stimulated with
50 ng/ml EGF for 30 min. Endogenous EGFR was stained with an
EGFR antibody, and the expressed proteins were detected using
a FLAG antibody. For quantitation, each Rab5-positive structure
that had a clear distinction between the lumen and the limiting
membrane was taken into account. Under each experimental condition, the localization of EGFR in either the lumen or the limiting
membrane of the Rab5 structure was assessed. For each condition
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